The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach (ITACA-S) trial: Comparison of a sequential treatment with irinotecan (CPT-11) plus 5-fluorouracil (5-FU)/folinic acid (LV) followed by docetaxel and cisplatin versus a 5-FU/LV regimen as postoperative treatment for radically resected gastric cancer.
Emilio Bajetta
No relevant relationships to disclose
Irene Floriani
No relevant relationships to disclose
Maria Di Bartolomeo
No relevant relationships to disclose
Roberto Labianca
No relevant relationships to disclose
Lorenza Landi
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose
Rossanna Casaretti
No relevant relationships to disclose
Enzo Pasquini
No relevant relationships to disclose
Francesca Di Fabio
No relevant relationships to disclose
Ermanno Rondini
No relevant relationships to disclose
Graziella Pinotti
No relevant relationships to disclose
Paolo Bidoli
No relevant relationships to disclose
Gerado Rosati
No relevant relationships to disclose
Andrea Mambrini
No relevant relationships to disclose
Andrea Ciarlo
No relevant relationships to disclose
Stefano Sergio Cordio
No relevant relationships to disclose
Sergio Ricci
No relevant relationships to disclose
Luca Frassineti
No relevant relationships to disclose
Francesco Di Costanzo
No relevant relationships to disclose
Anna Maria Bochicchio
No relevant relationships to disclose